Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Y2 - BRS - GI > GI cancers > Flashcards

GI cancers Flashcards

1
Q

What is cancer?

A

A term for diseases = abnormal cells divide without control and can invade nearby tissues

Cancer cells can also spread to other parts of the body through the blood and lymph systems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is a primary cancer?

What is a secondary or metastasis cancer?

A

Arising directly from the cells in an organ

Spread from another organ, directly or by other means (blood or lymph)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the first 6 hallmarks of cancer?

A

6 biological capabilities acquired by tumours =

Sustaining proliferative signalling

Evading growth suppressors

Activating invasion and metastasis

Enabling replicative immortality

Evading angiogenesis - blood supply for growing tumour mass

Resisting cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the emerging hallmarks of cancer?

A

Deregulating cellular energetics

Avoiding immune destruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the enabling characteristics of cancers?

A

What gives them selective advantage, acquired through genetic change AND/or epigenetic dysregulation (e.g. from chronic inflammation) =

Genome instability and mutation
Tumor promoting inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What do we know about cancer?

A

Cancer is a genetic disease

Cancers contain multiple genetic errors

Cancers contain more than just malignant cells - stromal cells, neovascular cells etc.

Killing cancer cells is easy

ONLY killing cancer cells is very hard and not affecting the normal cells around them

Developing novel therapies for cancer fraught with problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the cancers of the epithelial cells of the GI tract?

What are the cancers of the neuroendocrine cells of the GI tract?

What are the cancers of the connective tissue of the GI tract?

A

Squamous cell carcinoma - squamous
Adenocarcinoma - glandular epithelium

Neuroendocrine tumours - enteroendocrine cells
Gastrointestinal stromal tumours - interstitial cells of Cajal

Leiomyoma/Leiomyosarcomas - smooth muscle
Liposarcomas - adipose tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Where are GI neuroendocrine tumours found?

A

Throughout the GI tract, from the oesophagus to the stomach, duodenum pancreas, large bowel, small bowel and rectum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the most common GI cancer?

Why are GI cancers problematic?

A

Bowel (4th most common), but stomach, liver and pancreas cancer incidences are lower
2nd highest morbidity

Low incidence but high death rates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is essential for lessening cancer morbidity?

Why is there a higher 5 year survival rate for colorectal cancer compared to pancreatic or oesophageal?

A

Cancer screening - catching the disease early = better chance of resecting it = better chance of 5 year survival after diagnosis

Large bowel = has a mesentery and keeps to itself
Other GI cancers e.g. pancreatic, oesophageal, gallbladder = involve other structures v. quickly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is cancer screening?

A

Testing of asymptomatic individuals to identify cancer at an early stage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do we identify whether a disease is suitable for screening?

A

Wilson & Jungner criteria

Depends on the epidemiology of a disease & features of the test:

The condition should be an important health problem - and affecting a significant number of people to make it cost-effective to offer the screenings

There should be an accepted treatment for patients with disease

Facilities for diagnosis and treatment should be available

There should be a recognisable latent or early symptomatic stage

There should be a suitable test or examination

The test should be acceptable to the population - not too unpleasant where the population does not turn up to the test

The natural history of the condition, including development from latent to declared disease should be adequately understood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How is colorectal cancer screened for?

A

Offered to healthy individuals:

Faecal immunochemical test (FIT) - detects haemoglobin in faeces, every 2 years for everyone aged 60-74

One-off sigmoidoscopy for everyone aged >55 to remove polyps (reducing future risk of cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How is oesophageal cancer screened for?

A

Regular endoscopy to patients with:

Barrett’s oesophagus
OR
Have been found to previously had low- or high-grade dysplasia that has already been dealt with by local means rather than full resection for a full cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Are pancreatic and gastric cancers screened for?

A

No test exists that meets the W & J criteria

Depends on incidence - Japan screens for gastric cancer (high incidence): perform endoscopies
Makes economic and clinical sense to base this off incidence rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How is hepatocellular cancer screened for?

A 
Regular ultrasound & AFP (alpha faecal protein - tumour marker- looked for in a  blood test) for high-risk individuals:
With cirrhosis
OR
Viral hepatitis
OR
Alcoholic hepatitis
OR 
NASH (non alcoholic steatotic hepatitis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Who else is offered screening?

A

Specific screening programmes for those with genetic predisposition OR strong family histories

e.g. FAP (familial adenomatous polyposis) - multiple polyps in colon and duodenum, high risk of developing colorectal / duodenal cancer and so are offered prophylactic resections and yearly colonoscopies or OGD’s

OR

Hereditary pancreatitis - 40% lifetime risk of pancreatic cancer, offered prophylactic surgery and yearly imaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the cancer journey?

A

Diagnosis - What symptoms and signs does the patient present with? How is the diagnosis made?

Staging - What investigations are needed to see how advanced the cancer is?

Treatment - Can the cancer be surgically removed? What systemic therapy (e.f. chemotherapy) or radiotherapy is available?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How does a patients journey with cancer and the cancer MDT start?

A

Initial presentation to a member of the MDT:

Worrying symptoms to GP or another doctor (e.g. A&E)

OR

The patient is identified through a screening programme (e.g. faecal occult blood test for colon cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What happens next in the patient’s cancer journey involving the cancer MDT?

A

The patient is referred through the 2-week-wait cancer pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the third step in the cancer journey involving the Cancer MDT?

A

Diagnostic tests

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the fourth step in the cancer journey involving the Cancer MDT?

A

MDT - MDT meeting in which diagnostic test results are discussed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the fifth step in the cancer journey involving the Cancer MDT?

A

Treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Who is involved in the cancer MDT?

A 
Pathologist
Radiologist
Palliative care
Gastroenterologist
Oncologist
Surgeon
Cancer nurse specialist
25
Q

What is the role of the pathologist?

A

Confirms the diagnosis of cancer using biopsy samples

Provide histologic typing - what type of cell does the cancer come from? e.g. epithelium (squamous cell carcinoma) or secretory cells (adenocarcinoma); non-epithelial cells less common in the GI tract; neuroendocrine tumours (pancreas); or GI stromal tumours (GISTS) – (stomach)

Provide molecular typing - what type of mutations does this particular cancer have? Useful to determine treatment options available (e.g. which chemo will be most effective)

Provides the tumour grade - determines how aggressive the cancer is and how abnormal the cells and nuclei are; how actively are the cancer cells dividing

26
Q

What does the radiologist do?

A

Reviews scans:

  • Interprets the imaging
  • If diagnosis is unclear, comments on how likely the scan is to confirm cancer
  • Suggests other imaging to clarify suspected diagnosis
  • Should a biopsy be performed and from where?

Provides radiological tumour stage - i.e. how far has the cancer spread?
TNM system: T = size of Tumour; N = lymph Node involvement, M = presence of distant Metastases

Provides re-staging after treatment - did the cancer respond complete or partially? Has it remained stable or progressed

Interventional radiology - percutaneous biopsies, radiological stents

27
Q

What does the surgeon do?

A

Decides whether surgery is appropriate - works alongside gastroenterologist as they offer endoscopic means for diagnosing cancers and therapeutic interventions

Is the tumour resectable?
Is the patient fit enough for surgery?

Performs operation & cares for patient in perioperative period

28
Q

What does the gastroenterologist do?

A

Endoscopy – diagnostic & therapeutic

Upper GI
Oesophageal & gastric biopsies
Oesophageal stents

Liver & pancreas
ERCP & EUS biopsies
Biliary stents

Lower GI
Colonic biopsies
Colonic stents

29
Q

What do oncologists do?

A

Decide on whether chemotherapy, radiotherapy or other systemic therapy is appropriate - determined by the scans, histological type and molecular type; is the patient fit for full intensity therapy?

Coordinates the overall treatment plan - should chemotherapy come before surgery (neoadjuvant) or after (adjuvant); takes into consideration the type, grade and stage; also patient fitness and wishes

30
Q

Who decides what type of treatment plan the patient is getting and what are the different plan options?

A

MDT decides (taking into account the patients wishes)

Radical (Curative) VS palliative therapy (not a cure, but extending patient’s life) VS palliative care (no treatment at all, allow disease to progress)

31
Q

Who looks after cancer patients in palliative care?

A

Palliative care physicians

Also involves the cancer nurse specialist

32
Q

What is the major driver of gastric adenocarcinoma?

A

Anything causing a chronic gastritis

33
Q

What causes gastric adenocarcinoma?

A

Anything causing chronic gastritis, e.g.:

H.pylori infection
- due to inflammation into gastric mucosa esp. in the entrance of the stomach = duodenal ulcers = chronic acid overproduction = epithelium increasingly exposed to chemical attacks = metaplasia of epithelium = progresses to cancer

Pernicious anaemia
- autoantibodies against parts and products of parietal cells

Previous partial gastrectomy (e.g. for an ulcer) joins the small bowel to the stomach
- leading to bile reflux from the small bowel into stomach = predisposition to gastric cancers

Epstein-Barr virus infection

High salt diet & smoking

34
Q

What is important in the history taking to diagnose a cancer?

A

Family history (including heritable diffuse-type gastric cancer due to E-cadherin mutations)

Exposure to certain infections

35
Q

What is the pathogenesis / stages of gastric cancer progression?

A

Chronic gastritis - consists of surface cells, stem cells, parietal cells which are inflammed and atrophied, so the cells respond with hyperplasia

Intestinal metaplasia

Progresses to dysplasia

Becomes a cancer - malignancy

36
Q

What is the most common symptom of gastric cancer?

A

Dyspepsia (upper abdominal discomfort after eating or drinking)

37
Q

What are the red flags for gastric cancer?

A 
ALARMS55
Anaemia
Loss of weight or appetite
Abdominal mass on examination
Recent onset of progressive symptoms
Melaena or haematemesis
Swallowing difficulty
55 years of age or above
38
Q

How is gastric cancer diagnosed?

A

Endoscopy and biopsy

39
Q

How is gastric cancer staged (i.e. see how extensive the cancer is)?

A

CT of the chest (look for lung metastases), abdo (look for local metastases) & pelvis will provide information on distant lesions

PET-CT

Diagnostic laparoscopy - camera put inside patient to look at the peritoneal & liver for micro-metastases that are not picked up on PET scans, performed prior to full operation

Endoscopic ultrasound - will give most detail about local invasion, local vessel involvement, and node involvement

40
Q

What are the treatment options for gastric cancer?

A

Neoadjuvant chemotherapy - reducing the size of the tumour before surgery

Oesophago-gastrectomy

Total gastrectomy - if cancer is less than 5cm to the OG junction as the sphincter mechanism of the stomach cannot be saved

Subtotal gastrectomy - further than 5cm away from OG junction

Adjuvant chemotherapy

41
Q

What are the main features of Neuroendocrine tumours (NETs)?

A

Arise from the gastroenteropancreatic (GEP) tract (or bronchopulmonary system)

Relatively rare but diverse group of tumours

Regarded as common entity as they arise from secretory cells of the neuroendocrine system

42
Q

What causes NETs?

A

Sporadic tumours in 75%

But remaining 25% of patients have a genetic syndrome associated with it e.g.
Multiple Endocrine Neoplasia Type 1 (MEN1) - most common, involves:
- Parathyroid tumours
- Pancreatic tumours
- Pituitary tumours

43
Q

How NETs present clinically?

A

Most NETs are asymptomatic and found incidentally

Secretion of hormones and their metabolites in 40% of these e.g. serotonin, tachykinins (substance P), other vasoactive peptides etc.

BUT < 10% of NETs produce symptoms from those metabolites

44
Q

What are the consequences of NETs?

A

Can results in a variety of debilitating effects

Carcinoid syndrome - from secretion of serotonin from the tumour, causing:
Vasodilatation - flushing of face
Bronchoconstriction
Increased intestinal motility - diarrhoea
Endocardial fibrosis (PR & TR) = right sided heart problems e.g. right sided valvular lesions leading to incompetence / regurgitation

45
Q

How can a serotonin secreting tumour be asymptomatic?

A

E.g. if tumour is in the small bowel, the serotonin secreted enters the portal circulation and is metabolised by the liver - so in the absence of metastatic liver deposits there are no symptoms

VS

Bronchipulmonary carcinoids - releases serotonin directly into systemic circulation and so present with carcinoid syndrome in the absence of hepatic metastases

OR

Hepatic metastases that cannot metabolise the serotonin

46
Q

What is the most common NET?

How is it diagnosed clinically?

A

Pancreatic - Insulinoma - continuous production of insulin = too much insulin, causing

Hypoglycaemia
Diagnosed using - Whipple’s triad (symptoms of hypoglycaemia e.g. seizures, ‘drunk’, blurred vision etc., proven to have low plasma glucose at time of symptoms, symptoms relieved on eating)

47
Q

What ‘episodes’ do insulinoma patients often present with?

How does this lead to a misdiagnosis?

A

Hypoglycaemia leading to seizures
Relieved by eating

Often misdiagnosed with epilepsy

48
Q

What are the clinical features of glucagonoma?

A

Also pancreatic

Diabetes mellitus, necrolytic migratory erythema (red, blistering rash - spreads across skin at mouth and extremities)

Alpha cells

49
Q

What are the clinical features of gastrinomas?

A

Pancreatic and duodenal

Zollinger-Ellison syndrome

Too much gastrin production from gastrinoma = leading to peptic ulcers causing:

Abdominal pain and diarrhoea

50
Q

What are the clinical features of VIPomas?

A

Found within the entire GI tract

Too much VIP (vasoactive intestinal peptide) causing:

Verner-Morrison syndrome, watery diarrhoea

51
Q

What are the clinical features of somatostatinomas?

A

Entire GI tract

Gallstones, diabetes mellitus, steatorrhoea
D-cells

52
Q

What are the clinical features of midgut VS hindgut NETs?

A

Midgut = most are non-functioning, 40% develop carcinoid syndrome

Hindgut = most are non-functioning

53
Q

How do you diagnose NETs?

A

When suspected, investigations to localise the tumour / prove it is there, and confirm the diagnosis with histology

Biochemical Assessment =

  • Chromogranin A is a secretory product of NETs
  • Other gut hormones measured in fasting state: insulin, gastrin, somatostatin, PPY (associated with appetite)
  • Other screening: Calcium, PTH, prolactin, GH
  • 24 hr urinary 5-HIAA (serotonin metabolite)

Imaging =

  • Cross-sectional imaging (CT and/or MRI)
  • Bowel imaging (endoscopy, barium follow through, capsule endoscopy)
  • Endoscopic ultrasound (used to find pancreatic NETS)
  • Somatostatin receptor scintigraphy (as NETs tend to express somatostatin)
  • IV radio-labelled 68Ga-DOTATATE (somatostatin receptors) PET/CT most sensitive
54
Q

What is a capsule endoscopy?

A

Capsule containing camera
Swallowed
Passes through GI tract
Used to particularly look at small bowel due to difficulty accessing it via oral or rectal endoscopies

55
Q

How to we grade GEP-NETs?

A

Grade (1-3)
Mitoses
Ki-67 index

G1 = <2/10 H.P.F. = = 2%
G2 = 2-20/10 H.P.F. = 3-20%
G3 = >20/10 H.P.F. = >20%

Grade 3 = high grade (poorly differentiated) = neuroendocrine carcinoma

However, even in the lower grades, they act like cancers by metastasising often

56
Q

Why is the grading so important?

A

Useful to predict prognosis

57
Q

Which site metastasises the most?

A

Small intestine - metastasises especially to the liver, pancreas etc.

58
Q

What are the treatment modalities for NETs?

A

Curative resection (R0)

Cytoreductive resection (R1/R2)

Liver transplantation (OLTx)

RFA (radio frequency embolisation), microwave ablation

Embolisation (TAE - trans arterial embolisation = bland embolisation), chemoembolisation (TACE - trans artertial chemo embolisation)

Selective Internal RadioTherapy (SIRT)
- 90Y-Microspheres (radiolabelled somatostatin)

Somatostatin receptor radionucleotide therapy

  • 90Y-DOTA
  • 177 Lu-DOTA

Medical therapy, targeted therapy, biotherapy

  • Octreotide, Lanreotide, SOM203
  • PK-inhibitors, mTOR-inhibitors
  • ⍺-Interferon

Y2 - BRS - GI (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions